Coegin Pharma merges with Follicum
Coegin Pharma has announced successfully completing the merger acquisition of Lund-based diabetes company Follicum.
The company, currently conducting a phase I/II trial with lead candidate AVX001 in actinic keratosis and preclinical development of AVX420 in leukemia and chronic kidney diseaese. Through the merger Coegin strengthens its drug development portfolio by putting strong focus on diabetes complications.
Read more at Coegin Pharma